Microtubule-binding Agents Research Articles

Microtubule-stabilizing agents based on designed laulimalide analogues.

Laulimalide is a potent, structurally unique microtubule-stabilizing agent originally isolated from the marine sponge Cacospongia mycofijiensis. Laulimalide exhibits an activity profile different from other microtubule-binding agents, notably including effectiveness against paclitaxel-resistant cells, but it is intrinsically unstable. Five analogues of laulimalide were designed to exhibit enhanced chemical stability yet retain its exceptional biological activities. Evaluations of these analogues showed that all are effective inhibitors of cancer-cell proliferation yet differ substantially in potency with an IC(50) range of 0.12-16.5 microM. Although all of the analogues initiated cellular changes similar to laulimalide, including increased density of interphase microtubules, aberrant mitotic spindles, and ultimately apoptosis, differences among the analogues were apparent. The two most potent analogues, C(16)-C(17)-des-epoxy laulimalide and C(20)-methoxy laulimalide, appear to have a mechanism of action identical to laulimalide. The C(16)-C(17)-des-epoxy, C(20)-methoxy laulimalide derivative, which incorporates both chemical changes of the most potent analogues, was significantly less potent and initiated the formation of unique interphase microtubules unlike the parent compound and other analogues. Two C(2)-C(3)-alkynoate derivatives had lower potency, and they initiated abnormal microtubule structures but did not cause micronucleation or extensive G(2)/M accumulation. Significantly, paclitaxel- and epothilone-resistant cell lines were less resistant to the laulimalide analogues. In summary, analogues of laulimalide designed to minimize or eliminate its intrinsic instability have been synthesized, and some have been found to retain the unique biological activities of laulimalide.

Differential regulation of mitogen-activated protein kinases by microtubule-binding agents in human breast cancer cells.

Drug design targeted at microtubules has led to the advent of some potent anti-cancer drugs. In the present study, we demonstrated that microtubule-binding agents (MBAs) taxol and colchicine induced immediate early gene (c-jun and ATF3) expression, cell cycle arrest, and apoptosis in the human breast cancer cell line MCF-7. To elucidate the signal transduction pathways that mediate such biological activities of MBAs, we studied the involvement of mitogen-activated protein (MAP) kinases. Treatment with taxol, colchicine, or other MBAs (vincristine, podophyllotoxin, nocodazole) stimulated the activity of c-jun N-terminal kinase 1 (JNK1) in MCF-7 cells. In contrast, p38 was activated only by taxol and none of the MBAs changed the activity of extracellular signal-regulated protein kinase 2 (ERK2). Activation of JNK1 or p38 by MBAs occurred subsequent to the morphological changes in the microtubule cytoskeleton induced by these compounds. Furthermore, baccatine III and beta-lumicolchicine, inactive analogs of taxol and colchicine, respectively, did not activate JNKI or p38. These results suggest that interactions between microtubules and MBAs are essential for the activation of these kinases. Pretreatment with the antioxidants N-acetyl-L-cysteine (NAC), ascorbic acid or vitamin E, blocked H2O2- or doxorubicin-induced JNKI activity, but had no effect on JNKI activation by MBAs, excluding a role for oxidative stress. However, BAPTA/AM, a specific intracellular Ca2+ chelator, attenuated JNK1 activation by taxol but not by colchicine, and had no effect on microtubule changes induced by taxol. Thus, stabilization or depolymerization of microtubules may regulate JNK1 activity via distinct downstream signaling pathways. The differential activation of MAP kinases opens up a new avenue for addressing the mechanism of action of antimicrotubule drugs.

Detection of Pleiotropic Drug Resistance by the Rapid Immunofluorescence Assay of Drug Effects on the Cell Skeleton

We describe the development of an immunofluorescent method for the detection of resistance to agents which affect the integrity of the cellular microtubular network. Three pleiotropic resistant MCF-7 human breast carcinoma cell lines mixed with vaginal adenocarcinoma cells were selected in serially increasing drug concentrations, and demonstrated a 30-fold increase in resistance to colchicine. Transport studies indicated that there was no difference in drug accumulation between the sensitive and resistant lines. The colchicine-binding capacity of cell extracts from sensitive and resistant cells was similar (Kd for sensitive cells was 1.9 x 10(-6) M and for resistant cells 1.58 x 10(-6) M). There were, however, significant differences in cytoskeletal morphology between sensitive and resistant cells. Drug-sensitive cells were mostly large (about 70 microns 2) and flattened. Their cytoplasm was filled with a microtubular network in which, in most of the cases, single fibers could be differentiated. Cells usually had a microtubule-organizing center and paracortical bundles of microtubules. In contrast, drug-resistant cells were mostly rounded and grew in clumps. In only 40% of these cells could single microtubular fibers be differentiated. Resistant cells lacked a microtubule-organizing center and had no clear paracortical bundles of microtubules. The tubulin-binding agents tested caused a sequence of morphological changes in sensitive cells. These changes included precipitation of tubulin and disappearance of cytoskeletal structure. Changes occurred initially within 3 h of incubation, but were expressed in all cells after 6 h. If, after 3 h of drug exposure, cells were subcultured in drug-free media, the cytoskeletal structure reformed within 10 h. Maximal recovery of cytoskeletal structure occurred 22 h after drug removal and was sustained up to 36 h. In contrast to changes observed in sensitive cells, drug exposure did not induce changes in the morphology of cytoskeleton in resistant cells. Cells from all three resistant lines reverted to sensitivity after 7 months of culture in drug-free media. This was first detected by immunofluorescence and then confirmed by cloning assay. Since the cytoskeletal disintegration of sensitive cells is readily detectable within a few hours of in vitro drug treatment, immunofluorescent imaging may have its clinical application in predicting the sensitivity/resistance to microtubule-binding agents.

Hepatic processing of cholecystokinin peptides. II. Cellular metabolism, transport, and biliary excretion.

We have shown that radiolabeled cholecystokinin octapeptide (CCK-8), CCK-8-desulfate, and CCK-4 are extracted by the liver in a structurally specific manner. Thus, we studied the fate of the extracted radiolabeled peptides by quantitating biliary excretion and determining the nature of the metabolites in bile. There was rapid biliary excretion of labeled CCK-8, CCK-8-desulfate, and CCK-4 by the isolated, perfused rat liver; greater than 75% of the extracted dose and greater than 20% of the injected dose appeared in bile within 20 min after a single pass across the liver. By means of high-performance liquid chromatography and immunoprecipitation, we showed that CCK-8-desulfate and CCK-4 appeared in bile in completely metabolized forms. In contrast, for CCK-8, approximately 20% of the major forms of the label in bile was intact labeled octapeptide. To gain insight into the subcellular sites of metabolism and transhepatic transport of CCK-8, we also determined the effects of taurocholate, lysosomotropic agents, and microtubule binding agents on biliary excretion. Taurocholate had no effect on the percentage of the extracted label excreted into bile. Neither the percentage of the extracted label excreted into bile. Neither lysosmotropic agent, leupeptin, nor chloroquine affected the percentage of the extracted label or the nature of the metabolites appearing in bile. Two microtubule binding agents, vinblastine and colchicine, also did not affect the percentage of the extracted label appearing in bile.(ABSTRACT TRUNCATED AT 250 WORDS)

In vivo and in vitro effects of colchicine and vinblastine on the secretory process of antibody-producing cells.

The sensitivity of the secretory process of antibody-synthesizing cells to microtubule-binding drugs, colchicine and vinblastine sulfate, was studied. Rats were immunized by footpad injections of horseradish peroxidase, and the popliteal lymph nodes were removed at various times after injection. Both in vivo effects of colchicine and in vitro effects of colchicine and vinblastine were studied. Quantitative data were obtained with in vitro drug-treated cells by labeling with L-3H-leucine and by measuring the secreted and the cytoplasmic immunoglobulins. It was found that inhibition of immunoglobulin secretion was about 78% and 93% by colchicine and vinblastine, respectively. the results obtained with the latter drug were more difficult to interpret because it also inhibited the biosynthesis of total proteins, and particularly that of immunoglobulins. Immunocytochemical studies of the in vivo and in vitro drug-treated cells performed by light and electron microscopy showed that in antibody-containing cells the Golgi area was often occupied by dilated antibody-containing vesicles, probably derived from the Golgi apparatus. In a few of these cells it was observed that antibody-containing rough endoplasmic reticulum was markedly dilated. the above results demonstrate that both microtubule-binding agents, colchicine and vinblastine, are potent inhibitors of the secretory process of plasma cells and seem to indicate that a correlation may exist between ultrastructural changes and inhibition of secretion.